{
  "retracted": false,
  "timestamp": 1541030400000,
  "updates": [
    {
      "timestamp": 1585043987548,
      "identifier": {
        "doi": "10.1158/2159-8290.cd-18-1115"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1158/2159-8290.cd-16-1080"
  },
  "publisher": "American Association for Cancer Research (AACR)",
  "title": "Correction: Phase I Dose-Escalation Study of Taselisib, an Oral PI3KInhibitor, in Patients with Advanced Solid Tumors"
}
